drugset / Trial / NCT00019084
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
Treatment
Summary
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may be an effective treatment for advanced cancer. PURPOSE: Phase II trial to study the effectiveness of a vaccine made with the patients' white blood cells mixed with tumor proteins in treating patients who have advanced cancer.
Timeline
- Start
- 1996-02
- Primary completion
- —
- Completion
- 2003-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |
| Subject | mutant p53 peptide pulsed dendritic cell vaccine | Vaccine | — | — |
| Subject | ras peptide cancer vaccine | Vaccine | — | — |
| Subject | therapeutic autologous lymphocytes | Cell therapy | — | Other |
| Subject | therapeutic tumor infiltrating lymphocytes | Cell therapy | — | Other |
| Background | sargramostim | Protein / enzyme biologic | — | — |